Bavarian Biotech Report 2011/2012 (7MB) - Bio M
Share Embed Flag
Download ePaper

Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Bavarian Biotech Report 2011/2012 (7MB) - Bio M Bavarian Biotech Report 2011/2012 (7MB) - Bio M

m4.de
13.07.2015 Views

conoGenetix biosciences GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSContact:Dr. Andreas KlostermannAm Klopferspitz 19D-82152 MartinsriedPhone: +49 (0) 89 5472-6950Fax: +49 (0) 89 5472-6959E-Mail: info@conogenetix.deInternet: www.conogenetix.deKeywords: Cardiovascular Diseases, Pain, CNS, Peptide/Protein, DrugDevelopmentconoGenetix is a privately owned biopharmaceutical company focused onthe development of new peptide therapeutics for the treatment of autoimmunediseases. conoGenetix was founded in 2002 by Dr. AndreasKlostermann and Dr. Jörg Stockhaus and is located in Martinsried,Germany. The company has developed an integrated technology platformthat allows for the efficient discovery of drug leads that modulate ion channeltargets causatively involved in the generation of autoimmune diseases.conoGenetix runs a program targeting severe autoimmune disorders likeMultiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Vasculitis. Severalpeptides called cgtx-peptides within this program are in preclinical development.The leading indication for the cgtx-peptides will be Vasculitis; a fataldisease strongly related to Rheumatoid Arthritis. Vasculitis is a rare diseaseand will be a market door opener for conoGenetix.Contact:Jürgen SchäferNeuhauser Str. 47D-80331 MünchenPhone: +49 (0) 89 236650-0Fax: +49 (0) 89 236650-50E-Mail: schaefer@conreso.comInternet: www.conreso.comConreso GmbHCROKeywords: Clinical Research, Logistics, Monitoring, Drug DevelopmentConreso, established in 1990, BVMA member, offers a wide range of clinicalresearch services. Conreso shows an impressive record of successful FDAinspections and significant contributions to important new product licensesin Europe and the USA. Having recruited more than 30,000 patients between0 and 17 years of age proves the company’s unique expertise in pediatrictrials. The Hannover Clinical Trial Center, a joint venture of Conreso andthe Medizinische Hochschule Hannover, provides Conreso‘s clients access tothe clinical expertise and the comprehensive diagnostic and therapeuticfacilities of one of the leading academic medical institutions in Germany.The Conreso Institute of Veterinary medicine provides all types of veterinarystudies.50

Corimmun GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Inflammation, Cardiovascular Diseases, Peptide/Protein, DrugDevelopmentCORIMMUN is a spin-off from the universities of Wuerzburg and ofTuebingen. The projects are funded by two grants of the Go Bio project ofthe BMBF. Corimmun is financed by the MIG AG, KfW Bank, Bayernkapital,HTGF and Bio M AG. The company is developing new drugs to treat congestiveheart failure and atherosclerosis, the most common causes of mortalityin developed countries. Two innovative drugs, COR-1 and Revacept are currentlyin clinical development. COR-1 is a peptide drug candidate to preventthe auto-antibody-mediated propagation of heart failure. Revacept is alesion-specific inhibitor of atherothrombosis. Further preclinical candidatesare under development, i.e. COR-2 is a biological which prevents foam cellformation in atherosclerotic plaques. The founders and management ofCorimmun bring together knowledge and reputation in research and clinicalmedicine together with biotech experience.Contact:Dr. Goetz MünchFraunhoferstr. 17D-82152 MartinsriedPhone: +49 (0) 89 8565-2010Fax: +49 (0) 89 8565-2020E-Mail: info@corimmun.comInternet: www.corimmun.comCoriolis PharmaBIOTECH PRECLINICAL SERVICESKeywords: Analysis, Vaccines, Peptide/Protein, Lyophilization, Formulationdevelopment, Monoclonal Antibody, Supply preclinical materialCoriolis Pharma is a globally operating independent service provider forresearch and formulation development of (bio)pharmaceutical drugs(proteins, peptides, monoclonal antibodies, RNA/DNA etc.) and vaccines.An interdisciplinary team of highly qualified scientists with many years ofexperience in the development of (bio)pharmaceuticals provides cuttingedgeservice and know-how related to the formulation development of biopharmaceuticals,supported by an expert scientific advisory board.This may involve for example formulation development of (pre-)clinicalmaterial through to commercial products, lyophilization processes, stabilitytesting (light obscuration, Micro-Flow imaging and AF4/HF5 under cGMP),supply of pre-clinical material, and analytical services using innovative analyticaltechnologies.Contact:Dr. Michael WiggenhornAm Klopferspitz 19D-82152 MartinsriedPhone: +49 (0) 89 5424498-0Fax: +49 (0) 89 5424498-22E-Mail: contact@coriolis-pharma.comInternet: www.coriolis-pharma.com51

Corimmun GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Inflammation, Cardiovascular Diseases, Peptide/Protein, DrugDevelopmentCORIMMUN is a spin-off from the universities of Wuerzburg and ofTuebingen. The projects are funded by two grants of the Go <strong>Bio</strong> project ofthe BMBF. Corimmun is financed by the MIG AG, KfW Bank, Bayernkapital,HTGF and <strong>Bio</strong> M AG. The company is developing new drugs to treat congestiveheart failure and atherosclerosis, the most common causes of mortalityin developed countries. Two innovative drugs, COR-1 and Revacept are currentlyin clinical development. COR-1 is a peptide drug candidate to preventthe auto-antibody-mediated propagation of heart failure. Revacept is alesion-specific inhibitor of atherothrombosis. Further preclinical candidatesare under development, i.e. COR-2 is a biological which prevents foam cellformation in atherosclerotic plaques. The founders and management ofCorimmun bring together knowledge and reputation in research and clinicalmedicine together with biotech experience.Contact:Dr. Goetz MünchFraunhoferstr. 17D-82152 MartinsriedPhone: +49 (0) 89 8565-2010Fax: +49 (0) 89 8565-2020E-Mail: info@corimmun.comInternet: www.corimmun.comCoriolis PharmaBIOTECH PRECLINICAL SERVICESKeywords: Analysis, Vaccines, Peptide/Protein, Lyophilization, Formulationdevelopment, Monoclonal Antibody, Supply preclinical materialCoriolis Pharma is a globally operating independent service provider forresearch and formulation development of (bio)pharmaceutical drugs(proteins, peptides, monoclonal antibodies, RNA/DNA etc.) and vaccines.An interdisciplinary team of highly qualified scientists with many years ofexperience in the development of (bio)pharmaceuticals provides cuttingedgeservice and know-how related to the formulation development of biopharmaceuticals,supported by an expert scientific advisory board.This may involve for example formulation development of (pre-)clinicalmaterial through to commercial products, lyophilization processes, stabilitytesting (light obscuration, Micro-Flow imaging and AF4/HF5 under cGMP),supply of pre-clinical material, and analytical services using innovative analyticaltechnologies.Contact:Dr. Michael WiggenhornAm Klopferspitz 19D-82152 MartinsriedPhone: +49 (0) 89 5424498-0Fax: +49 (0) 89 5424498-22E-Mail: contact@coriolis-pharma.comInternet: www.coriolis-pharma.com51

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!